Structure-function analysis of tight junction-directed permeation enhancer PIP250.

J Control Release

Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath BA2 7AY, UK. Electronic address:

Published: October 2023

The intestinal paracellular route of absorption is modulated via tight junction (TJ) structures located at the apical neck of polarized intestinal epithelial cells to restrict solute movement through the intercellular space between them. Tight junctions open or close in response to changes in the phosphorylation status of light chain (MLC) at position Ser-19. This phosphorylation event is primarily controlled by MLC kinase (MLCK) and MLC phosphatase (MLCP), the latter being a holoenzyme that involves interaction between protein phosphatase 1 (PP1) and myosin targeting protein 1 (MYPT1). An entirely D-amino acid Permeant Inhibitor of Phosphatase (PIP) peptide sequence designed to disrupt PP1-MYPT1 interactions at the cytoplasmic surface of TJs, PIP250 (rrfkvktkkrk) localized at intracellular TJ structures, altered expression levels of specific TJ proteins, increased cellular phosphorylated MLC (pMLC) levels, binding to PP1, decreased epithelial barrier function, and significantly increased systemic uptake of the poorly absorbed antibiotic gentamicin in vivo. A series of PIP250 peptide analogues showed that positions phe3 and val5 were critical to its functional properties, with some providing opportunities to tune the dynamic actions of its TJ modulation properties. These data confirm the activity of PIP250 as a rationally designed oral permeation enhancer and validated key amino acids involved in its interaction with PP1 that define its overall actions; the magnitude and duration of these enhancing properties were associated with the MYPT1-mimetic properties of the PIP250 peptide analogues described.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2023.10.044DOI Listing

Publication Analysis

Top Keywords

permeation enhancer
8
pip250 peptide
8
peptide analogues
8
pip250
5
structure-function analysis
4
analysis tight
4
tight junction-directed
4
junction-directed permeation
4
enhancer pip250
4
pip250 intestinal
4

Similar Publications

Poor aqueous solubility and bioavailability limit the translation of new drug candidates into clinical applications. Nanocrystal formulations offer a promising approach for improving the dissolution rate and saturation solubility. These formulations are applicable for various routes of administration, with each presenting unique opportunities and challenges posed by the physiological barriers.

View Article and Find Full Text PDF

The surge in plastic production has spurred a global crisis as plastic pollution intensifies, with microplastics and nanoplastics emerging as notable environmental threats. Due to their miniature size, these particles are ubiquitous across ecosystems and pose severe hazards as they are ingested and bioaccumulate within organisms. Although global plastic production has reached an alarming 400.

View Article and Find Full Text PDF

Oil spills and industrial oily wastewater pose serious threats to the environment. A series of modified membranes with special wettability have been widely used for separating oil/water mixtures and emulsions. However, these membranes still face challenges such as the detachment of the modified coatings and membrane fouling.

View Article and Find Full Text PDF

Lipophilic derivatives of vitamin C, known as ascorbyl-6-O-alkanoates (ASCn), have been mainly developed for use in cosmetics, pharmaceuticals, and the food industry as antioxidant additives. These derivatives are of biotechnological interest due to their antioxidant properties, amphiphilic behavior, capacity to self-organize into nano- and micro-structures, anionic nature, and low cost of synthesis. In this review, we will focus on the commercial amphiphile, 6-O-palmitoyl L-ascorbic acid (ASC16), and the shorter acyl chains derivatives, such as 6-O-myristoyl (ASC14) and 6-O-lauroyl L-ascorbic acid (ASC12).

View Article and Find Full Text PDF

Restenosis remains a long-standing limitation to effectively maintain functional blood flow after percutaneous transluminal angioplasty (PTA). While the use of drug-coated balloons (DCBs) containing antiproliferative drugs has improved patient outcomes, limited tissue transfer and poor therapeutic targeting capabilities contribute to off-target cytotoxicity, precluding adequate endothelial repair. In this work, a DCB system was designed and tested to achieve defined arterial delivery of an antirestenosis therapeutic candidate, cadherin-2 (N-cadherin) mimetic peptides (NCad), shown to selectively inhibit smooth muscle cell migration and limit intimal thickening in early animal PTA models.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!